Switzerland and London-based startup Caeli Nova has reportedly closed its Series A funding, having secured €7.7 million in a round spearheaded by LG Capital and backed by Ornament Health. However, the round also saw the participation of investors which includes Latécoère.
The startup which is evolving its innovation at the intersection of aviation and healthcare was founded in 2018 with the aim to improve human safety and performance via the application of medical science. Moreover, it is believed the subject company has developed and patented new breathing technology that enhances oxygenation in challenging environments – notably at altitude.
As for the inspiration, evolved when one of the founders of the subject company boarded a flight from Hong Kong to Europe, while on transit, figured out that the aircraft wasn’t taking the most direct flight. He eventually got across to the captain, in the process, it was uncovered that pilots are required to follow routes that allow for rapid descent to a safe altitude in the rare event of an emergency decompression as a result of limiting factors in the aircraft’s oxygen system. In view of this, its evident aircraft are frequently avoiding more direct routes to avoid high terrain routes while compensating for oxygen systems.
Therefore, to overcome limitations associated with the existing technology, startup Caeli Nova launch Cordillera, an advanced product for aircraft emergency oxygen systems that practically overcome the existing limitations, while significantly reducing costs coupled with carbon emissions for airlines by enabling aircraft to fly the most direct routes. To this end, the company plans to install Cordillera onto the first aircraft in this year 2022.
Caeli Nova CEO ‘Tim Wakeford’ made clear: “We’re very excited to be moving forward with our new investors in this financing round, including Ornament Health and Latécoère, to advance Cordillera’s benefits for air carriers. Their support will provide a valuable foundation for the first installations of our technology in the aviation market. We further would like to leverage our technology to explore its application in other markets, for example providing better oxygenation to patients across clinical and hospital settings”.
Currently, the subject startup with offices in the UK and Switzerland now has a team of 40 specialists from across the medical and aerospace sectors. While the latest fundraised will enable the breathing technology developer to take greater strides in scaling its technology, also in order to bring its first products to the market.
- What’s your opinion over the subject product?